Investigation of Bisphosphonate Therapy for Osteoporosis: A Single‐Center Cross‐Sectional Study
Journal of General and Family Medicine · 2026-05 · 27 (3)
DOI: 10.1002/jgf2.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of General and Family Medicine, online erschienen am 13.05.2026. Verfasst von Taku Harada und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine Nerima Hikarigaoka Hospital Tokyo Japan. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aimed to examine the management of bisphosphonate (BP) therapy for osteoporosis in Japan, focusing on treatment duration, dual‐energy X‐ray absorptiometry (DXA) assessment status, therapy despite renal impairment, and history of atypical femoral fracture (AFF).
Methods
This single‐center, cross‐sectional study included 117 women inpatients aged ≥ 65 years admitted to the Department of General Medicine at Nerima Hikarigaoka Hospital between October 2022 and September 2025 while receiving BP therapy. The primary outcome was the prevalence of ultra‐long‐term therapy (≥ 10 years oral or ≥ 6 years intravenous). Secondary outcomes included long‐term therapy (≥ 5 years oral or ≥ 3 years intravenous), unknown treatment duration, inadequate DXA assessment, therapy despite renal impairment (serum creatinine ≥ 1.5 mg/dL), and AFF history.
Results
The mean age was 84.3 ± 7.1 years. Ultra‐long‐term therapy occurred in 5.1% of patients, long‐term therapy in 23.1%, unknown treatment duration in 29.9%, and inadequate DXA assessment in 49.6%. Therapy despite renal impairment was noted in 6.8%, and one patient (0.8%) had AFF. Unknown treatment duration and inadequate DXA assessment were significantly more common in nonorthopedic care and in facility‐ or home‐based settings ( p < 0.01).
Conclusions
Among older women in Japan, ultra‐long‐term BP therapy was rare; however, nearly half lacked adequate assessment of treatment duration or documented DXA evaluation. These findings reveal shortcomings in long‐term osteoporosis management, particularly in nonorthopedic and facility‐ or home‐based care settings. Standardized reassessment, appropriate DXA evaluation, and improved information sharing across care transitions are essential to optimize treatment quality and safety in an aging population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Medicine Nerima Hikarigaoka Hospital Tokyo Japan.
- Department of Generalist Medicine Dokkyo Medical University Hospital Tochigi Japan.
- Department of Hospital General Medicine Tokyo Metropolitan Hiroo Hospital Tokyo Japan.
ORCID-Profile: Taku Harada, Shintaro Kosaka
Zitieren
APA
Harada, T., & Kosaka, S. (2026). Investigation of Bisphosphonate Therapy for Osteoporosis: A Single‐Center Cross‐Sectional Study. Journal of General and Family Medicine, 27(3). https://doi.org/10.1002/jgf2.70126
Vancouver
Harada T, Kosaka S. Investigation of Bisphosphonate Therapy for Osteoporosis: A Single‐Center Cross‐Sectional Study. Journal of General and Family Medicine. 2026;27(3). doi:10.1002/jgf2.70126
BibTeX
@article{Harada2026,
author = {Harada, Taku and Kosaka, Shintaro},
title = {Investigation of Bisphosphonate Therapy for Osteoporosis: A Single‐Center Cross‐Sectional Study},
journal = {Journal of General and Family Medicine},
year = {2026},
volume = {27},
number = {3},
doi = {10.1002/jgf2.70126}
}
EUVIMED